Maze Therapeutics

Bio Health Biopharma Biotechnology Genetics Therapeutics

0 open

South San Francisco, California, United StatesFounded 2019146+ employeesGrowth raisedGrowthMAZE

Last round: post ipo equity · $150M · Sep 2025(5 rounds total)

Founded by Charles Homcy, Sekar Kathiresan, Mark Daly, Stephen Elledge, Aaron D. Gitler, Jonathan S. Weissman“Translating human genetics insights into a pipeline of novel precision therapies for common diseases”

Backed by(23 investors)

Deep Track CapitalFrazier Life SciencesARCH Venture PartnersCity Hill VenturesMatrix Capital ManagementThird Rock VenturesVenrock Healthcare Capital PartnersDriehaus Capital ManagementLogos CapitalJanus Henderson InvestorsTCG CrossoverPiper Heartland Healthcare CapitalAndreessen HorowitzGeneral CatalystForesite Capital

Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows it to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. The company’s pipeline is led by two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease. Maze is based in South San Francisco.